Paper Details

  1. Home
  2. Paper Details

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.

Author: BrownAndrew, BrownClare, ConaghanPhilip G, EmeryPaul, FraserAlexander, GreensteinAdam, JarretStephen, KarimZunaid, O'ConnorPhilip J, QuinnMark A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This 12-month study investigated the effectiveness of using infliximab (an anti-TNFalpha drug) in combination with standard treatment to achieve remission in patients with early rheumatoid arthritis (RA) who had a poor prognosis. The study primarily looked at joint inflammation (synovitis) using MRI and continued follow-up for another 12 months.
Paper Details　
Original Abstract of the Article :
Anti-tumor necrosis factor alpha agents are among the most effective therapies for rheumatoid arthritis (RA). However, their optimal use is yet to be determined. This 12-month double-blind study attempted remission induction using standard therapy with or without infliximab in patients with early, p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/art.20712

データ提供：米国国立医学図書館（NLM）

Early Treatment with Infliximab for Rheumatoid Arthritis: A Path Towards Remission

Rheumatoid arthritis (RA) can feel like a relentless desert storm, causing joint pain, inflammation, and stiffness. This study explores the potential benefits of early treatment with infliximab, a medication used to suppress the immune system, in individuals with early, poor-prognosis RA. The study investigates the effectiveness of infliximab in reducing inflammation and damage in these patients, comparing its effects to standard therapy alone.

A Promising Oasis: Early Treatment with Infliximab for RA

This study suggests that early treatment with infliximab, in addition to methotrexate, can significantly reduce inflammation and damage in patients with early, poor-prognosis RA. The study found that infliximab led to significant reductions in synovitis, a marker of inflammation, as measured by magnetic resonance imaging (MRI). This suggests that early intervention with infliximab could offer a valuable tool for managing RA, potentially preventing long-term damage and improving patient outcomes.

A Sustainable Journey: The Long-Term Benefits of Early Treatment

The study's findings have long-term implications, suggesting that early treatment with infliximab could lead to sustained benefits even after the medication is withdrawn. This finding is promising, like discovering a hidden spring that continues to flow long after the caravan has passed. It suggests that early intervention with infliximab could help patients achieve long-term remission, significantly improving their quality of life and reducing the long-term impact of RA.

Dr. Camel's Conclusion

This study underscores the importance of early and aggressive treatment for RA. It demonstrates the potential benefits of infliximab in achieving remission, even in patients with poor-prognosis. This research provides valuable insights into the potential for early intervention to shape long-term outcomes for individuals with RA, offering a path towards a more fulfilling life in the face of this challenging condition.

Date :
  1. Date Completed 2005-02-15
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

15641102

DOI: Digital Object Identifier

10.1002/art.20712

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.